Keratoacanthoma - Queratoacantoma
☆ AI Dermatology — Free Service
Nos resultados de Stiftung Warentest de Alemaña de 2022, a satisfacción dos consumidores con ModelDerm foi só lixeiramente inferior á das consultas de telemedicina pagas.
Nos resultados de Stiftung Warentest de Alemaña de 2022, a satisfacción dos consumidores con ModelDerm foi só lixeiramente inferior á das consultas de telemedicina pagas.
Queratoacantoma típico (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) é un tumor da pel frecuente, coñecido polo seu rápido crecemento e polo seu potencial para regresarse por sí mesmo. Adoita ocorrer en homes de maior idade e de pel clara, con antecedentes de danos solares. Aínda que a extirpación quirúrxica mediante escisión ou cirurxía micrográfica de Mohs é o tratamento habitual, existen outras opcións terapéuticas dispoñibles.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) é un tumor de baixo grao que se origina en certas glándulas da pel e se parece ao squamous cell carcinoma (SCC) ao microscopio. Hai un debate en curso sobre se o KA debería clasificarse como unha forma de SCC invasivo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) é o segundo tipo de cancro máis frecuente nas persoas, especialmente nas persoas maiores. A cirurxía adoita empregarse para tratar o cSCC, pero para algúns pacientes que non poden operarse ou que prefiren non facelo, pódense considerar outras opcións, como os tratamentos intralesionais. Utilizáronse tratamentos intralesionais tradicionais (methotrexate ou 5-fluorouracil), pero hai investigacións en curso sobre novos enfoques, como a inmunoterapia intralesional e a viroterapia oncolítica. Aquí analizaremos diferentes tratamentos intralesionais para o cSCC, que van desde métodos clásicos ata estratexias de vangarda.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Ao microscopio, o queratoacantoma (Keratoacanthoma) parécese moito ao carcinoma de células escamosas. Aínda que algúns patólogos clasifican o queratoacantoma (Keratoacanthoma) como unha entidade distinta e non como un tumor maligno, preto do 6 % dos queratoacantoma (Keratoacanthoma) clínicos e histolóxicos progresan a carcinomas de células escamosas invasivas e agresivas.
○ Diagnóstico e Tratamento
#Dermoscopy
#Skin biopsy